Research programme: tissue kallikrein serine protease inhibitors - Med Discovery/Dermadis

Drug Profile

Research programme: tissue kallikrein serine protease inhibitors - Med Discovery/Dermadis

Alternative Names: DIM-107; DM 107; hK2 inhibitors; MDKP 67b; RIK-7

Latest Information Update: 20 Apr 2016

Price : $50

At a glance

  • Originator Med Discovery
  • Developer Dermadis; Med Discovery; University of Zurich
  • Class
  • Mechanism of Action Peptide hydrolase inhibitors; Serine endopeptidase inhibitors; Tissue kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital ichthyosiform erythroderma
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atopic dermatitis; Congenital ichthyosiform erythroderma; Neutropenia; Prostate cancer; Psoriasis

Most Recent Events

  • 23 Sep 2010 Preclinical trials in Congenital ichthyosiform erythroderma in France (Topical)
  • 23 Mar 2010 Preclinical trials in Atopic dermatitis in France (Topical)
  • 23 Mar 2010 Preclinical trials in Psoriasis in France (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top